Jpmorgan Chase & CO Emergent Bio Solutions Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 649,502 shares of EBS stock, worth $5.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
649,502
Previous 273,540
137.44%
Holding current value
$5.7 Million
Previous $692,000
540.03%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EBS
# of Institutions
147Shares Held
30.4MCall Options Held
137KPut Options Held
706K-
Black Rock Inc. New York, NY3.84MShares$33.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.67MShares$32.2 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA3.17MShares$27.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.24MShares$10.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny946KShares$8.3 Million0.0% of portfolio
About Emergent BioSolutions Inc.
- Ticker EBS
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 49,861,500
- Market Cap $437M
- Description
- Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...